Please ensure Javascript is enabled for purposes of website accessibility

Moderna, Pfizer, Johnson & Johnson, And Others To Make Pledge in Response to Coronavirus Vaccine Political Pressure

By Brian Orelli, PhD – Sep 4, 2020 at 8:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A quick approval would be nice, but the drugmakers are sticking to their scientific principals.

With the U.S. presidential election scheduled around the same time that the first coronavirus vaccines will be up for potential authorization or approval by the Food and Drug Administration (FDA), there's been a lot of speculation that the current administration might pressure the agency to approve a vaccine before the election.

Coronavirus vaccine developers are apparently putting that theory to rest according to a report by Bloomberg. The companies, which reportedly include Pfizer (PFE 0.74%), Moderna (MRNA -0.23%), Johnson & Johnson (JNJ 0.13%), GlaxoSmithKline (GSK 0.89%), Sanofi (SNY 0.78%), and potentially others, plan to issue a statement pledging not to send any coronavirus vaccine to the FDA unless it has extensive safety and efficacy data. The statement could come as early as next week according to Bloomberg's sources.

Pfizer and its partner BioNTech (BNTX -0.88%) have said they expect to have enough early-stage data from their phase 3 study in October to submit an application to the FDA. Last week, the Financial Times reported that AstraZeneca (AZN 0.08%) might have its coronavirus vaccine authorized by the FDA before the election, although the British drugmaker said it hadn't discussed the possibility with the agency.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

The vaccine-maker pact downplays enthusiasm for a vaccine timeline suggested by President Donald Trump, who reportedly said he expects a vaccine could be ready "maybe even before November first" during a news conference at the White House on Friday.

The FDA has scheduled a meeting of outside experts on October 22 to discuss coronavirus vaccine development, although it isn't clear at this point which specific vaccines might be discussed.

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.24 (0.13%) $0.23
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41
Sanofi Stock Quote
Sanofi
SNY
$45.39 (0.78%) $0.35
GSK plc Stock Quote
GSK plc
GSK
$33.99 (0.89%) $0.30
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.17 (0.08%) $0.05
BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.